Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CSPC PHARMACEUTICAL GROUP LIMITED
石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

UNAUDITED FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2026

In compliance with the relevant requirements of Shenzhen Stock Exchange, CSPC Innovation Pharmaceutical Co., Ltd. ("**CSPC Innovation**"), a subsidiary of CSPC Pharmaceutical Group Limited (the "**Company**") listed on the ChiNext Market of Shenzhen Stock Exchange (Stock Code: 300765), published its unaudited third quarterly report for the nine months ended 30 September 2026 (the "**2026 Third Quarterly Report**") on 28 October 2026 on the information disclosure webpage of Shenzhen Stock Exchange's website at http://www.szse.cn/disclosure/listed/notice/index.html. CSPC Innovation's financial information was prepared in accordance with the China Accounting Standards for Business Enterprises.

Set out in the appendices to this announcement (the "**Appendices**") is the principal financial data of CSPC Innovation extracted from the 2026 Third Quarterly Report prepared in Chinese. In case of any inconsistency between the Chinese version and the English version, the Chinese version shall prevail.

Shareholders and potential investors of the Company are reminded that the financial information of CSPC Innovation in the 2026 Third Quarterly Report and in the Appendices is unaudited consolidated financial information of CSPC Innovation for the nine months ended 30 September 2026, rather than that of the Company. They should exercise caution when dealing in the securities of the Company.

By Order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 28 October 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.

APPENDIX I

KEY ACCOUNTING DATA AND FINANCIAL INDICATORS

Currency: RMB

	Current reporting period	Increase/decrease of the current reporting period compared with the corresponding period of last year	From the beginning of the year to the end of the reporting period	Increase/decrease from the beginning of the year to the end of the reporting period compared with the corresponding period of last year
Operating revenue (Yuan)	736,214,032.06	35.47%	3,976,456,258.17	149.62%
Net profit attributable to shareholders of the listed company (Yuan)	-51,329,029.38	-140.95%	1,209,856,961.94	5,130.83%
Net profit attributable to shareholders of the listed company after deducting non-recurring profit or loss (Yuan)	-73,804,709.10	-211.72%	1,152,127,009.43	1,877.40%
Net cash flow generated from operating activities (Yuan)	—	—	2,671,053,802.09	1,625.26%
Basic earnings per share (Yuan/share)	-0.0369	-141.18%	0.8688	5,121.97%
Diluted earnings per share (Yuan/share)	-0.0369	-141.18%	0.8688	5,121.97%
Weighted average return on net assets	-1.31%	-0.74%	36.91%	37.56%
	At the end of the current reporting period	**At the end of last year**	**Increase/decrease at the end of the current reporting period compared with the end of last year**	
Total assets (Yuan)	8,205,164,174.74	6,276,311,291.82	30.73%	
Equity attributable to shareholders of the listed company (Yuan)	3,888,043,294.05	2,667,343,683.63	45.76%	

NON-RECURRING PROFIT OR LOSS ITEMS AND AMOUNTS

Unit: Yuan Currency: RMB

Items	Amount for the current reporting period	Amount from the beginning of the year to the end of the reporting period	Description
Gains/losses on disposal of non-current assets (including the portion offset with the provision for impairment of assets)	-459,490.30	-735,582.80	
Government grants recognised in profit or loss for the current period (excluding those closely related to the company's normal business operations, complied with national policies, granted according to established standards, and continuously affecting the company's profit or loss)	19,627,646.47	58,421,489.13	
Profit or loss from changes in fair value of financial assets and financial liabilities and profit or loss from disposal of financial assets and financial liabilities held by non-financial enterprises, other than effective hedging activities related to normal business operations of the company	9,549,249.71	15,503,460.00	
Non-operating income and expenses other than the items above	-989,855.90	-2,153,610.48	
Less: Impact of income tax	92,483.37	390,015.84	
Impact of minority interests (after tax)	5,159,386.89	12,915,787.50	
Total	22,475,679.72	57,729,952.51	—

APPENDIX III

CHANGES IN MAJOR ACCOUNTING DATA AND FINANCIAL INDICATORS AND THE REASONS THEREOF

Unit: Yuan Currency: RMB

1. Major items of consolidated balance sheet

Items	30 September 2026	31 December 2025	Changes	Reasons for changes
Cash and bank balances	1,033,440,730.49	772,169,026.93	33.84%	Mainly due to the receipt of upfront payments by Megalith Biopharmaceutical from AstraZeneca during the reporting period.
Financial assets held for trading	1,429,778,493.50	385,387,333.34	271.00%	Mainly due to the company's increased purchase of cash management products from banks during the reporting period.
Trade receivables	646,324,881.24	441,330,765.53	46.45%	Mainly due to the receivables arising from the recognition of out-licensing revenue by Megalith Biopharmaceutical during the reporting period.
Prepayments	159,705,509.61	72,757,509.02	119.50%	Mainly due to the upfront payment of clinical trials made for multiple products in the clinical R&D stage during the reporting period.
Long-term equity investments	29,099,448.83	259,224,939.15	-88.77%	Mainly due to the disposal of the equity interest in the investee, Beijing Guoxin Huijin Co., Ltd., during the reporting period.
Long-term borrowings	244,314,782.35	0.00	Not applicable	Mainly due to new bank loans obtained during the reporting period.
Contract liabilities	239,702,380.54	26,085,436.73	818.91%	Mainly due to the receipt of upfront payments by Megalith Biopharmaceutical from AstraZeneca during the reporting period.

2. Major items of consolidated income statement

Items	January to September 2026	January to September 2025	Changes	Reasons for changes
Operating revenue	3,976,456,258.17	1,593,014,097.66	149.62%	Mainly due to the recognition of revenue by Megalith Biopharmaceutical under the Strategic Collaboration and License Agreement entered into with AstraZeneca during the reporting period.
Management expenses	95,720,231.00	64,144,771.03	49.23%	Mainly due to the increase in depreciation resulting from the transfer of certain construction-in-progress of Megalith Biopharmaceutical to fixed assets and the increase in staff costs for management personnel during the reporting period.
Research and development expenses	970,261,382.64	683,435,255.69	41.97%	Mainly due to a substantial increase in R&D expenses, resulting from multiple products of Megalith Biopharmaceutical being in the clinical R&D stage and the continued increase in pipeline products entering Phase III clinical trials during the reporting period.
Financial expenses	48,593,304.92	-20,545,075.30	336.52%	Mainly due to the increase in foreign exchange losses resulting from the appreciation of the RMB against the US dollar and the increase in interest expenses during the reporting period.
Gains/losses from changes in fair value	15,503,460.00	448,458.33	3,357.06%	Mainly due to the company's increased purchase of bank cash management products from banks during the reporting period.

3. Major items of consolidated statement of cash flows

Items	January to September 2026	January to September 2025	Changes	Reasons for changes
Net cash flow generated from operating activities	2,671,053,802.09	-175,121,559.93	1,625.26%	Mainly due to the receipt of upfront payments of US$420 million by Megalith Biopharmaceutical under the Strategic Collaboration and License Agreement entered into with AstraZeneca during the reporting period.
Net cash flow generated from investing activities	-1,713,672,445.38	-244,872,397.40	599.82%	Mainly due to the changes in the company's purchase and redemption of cash management products from banks during the reporting period.
Net cash flow generated from financing activities	-660,162,158.12	340,066,748.32	-294.13%	Mainly due to the company's payment of the consideration for the acquisition of minority equity interests in Megalith Biopharmaceutical and the repayment of loans from related companies during the reporting period.